Menu
Search
|

Menu

Close
X

Regulus Therapeutics Inc RGLS.OQ (NASDAQ Stock Exchange Global Market)

1.16 USD
-0.04 (-3.33%)
As of Feb 23
chart
Previous Close 1.20
Open 1.20
Volume 64,735
3m Avg Volume 95,563
Today’s High 1.23
Today’s Low 1.14
52 Week High 1.92
52 Week Low 0.79
Shares Outstanding (mil) 103.79
Market Capitalization (mil) 142.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.43 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
21
EPS (USD)
FY17
-0.784
FY16
-1.550
FY15
-1.089
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
551.11
5.77
Price to Book (MRQ)
vs sector
3.64
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
99.17
16.52
LT Debt to Equity (MRQ)
vs sector
99.17
12.22
Return on Investment (TTM)
vs sector
-95.74
14.43
Return on Equity (TTM)
vs sector
-149.70
16.13

EXECUTIVE LEADERSHIP

Stelios Papadopoulos
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Joseph Hagan
President, Chief Executive Officer, Principal Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Daniel Chevallard
Chief Financial Officer, Principal Financial and Accounting Officer, Since 2017
Salary: --
Bonus: --
Mark Deeg
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
B. Lynne Parshall
Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10614 Science Center Dr
SAN DIEGO   CA   92121-1150

Phone: +1858.2026300

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

SPONSORED STORIES